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This issue of Therapeutics and Clinical Risk Management contains original articles 
that address two very different but important clinical issues namely improving diag-
nostic imaging in carcinoma of the bladder and an observational study that evaluated 
the association between metabolic syndrome and high homocysteinemia (HHcy) in 
relation to cardiovascular disease. Atopic dermatitis (AD) is a distressing and com-
mon chronic relapsing cutaneous disease that has signiﬁ  cant impact on the quality of 
life of those affected. It is seen more frequently in children and the symptoms of AD 
include dry and scaly skin and intense itching. The latter symptom leads to an itching-
scratching cycle that exacerbates the condition, particularly in young children. Triggers 
for the condition include allergens, microbial infections and a disrupted skin barrier 
function. Corticosteroids represent the treatment of choice for AD as they target the 
T-cell driven inﬂ  ammatory response that underlies the pathogenesis of AD. Emol-
lients are also important treatments as they provide relief for the dry and ﬂ  aky skin 
characteristic of AD. It is of interest therefore that Lee and colleagues (2007) have 
provided a comprehensive review in the current issue on pimecrolimus, an ascomy-
cin macrolactam derivative developed speciﬁ  cally for the treatment of inﬂ  ammatory 
skin diseases. Currently, pimecrolimus has been approved as second line therapy for 
the treatment of mild to moderate AD in non-immunocompromized children over 2 
years old and in adult patients. Pimecrolimus has high afﬁ  nity for macrophilin-12, a 
cytosolic T-cell receptor, and this interaction blocks the activity of the calcium de-
pendent phosphatase calcineurin. This in turn prevents the transcription factor NF-AT 
activating genes that encode the TH2-type cytokines IL-4, IL-10 and the TH1-type 
cytokines IL-2 and IFN-γ. Pimecrolimus also decreases cytokine production and the 
release of preformed mediators from mast cells. These beneﬁ  cial effects in modulat-
ing the inﬂ  ammatory processes in the skin of AD patients must be tempered with the 
potential side effects of this treatment – issues compressively addressed in this article. 
The authors highlight several clinical trials demonstrating the long-term safety and ef-
ﬁ  cacy of pimecrolimus in pediatric and adult patients suffering from mild to moderate 
AD. The article also discusses data from the recent ISOLATE trial (Zuberbier et al 
2006) which assessed the impact of AD on patients’ quality of life including the social 
and emotional consequences of the condition. Moreover, topical anti-inﬂ  ammatory 
therapy with pimecrolimus was associated with signiﬁ  cant improvement in quality of 
life over the 6 month study period together with a signiﬁ  cant steroid sparing effect. 
The authors concluded that topical anti-inﬂ  ammatory therapy has an important place 
in long term AD treatment.
The skin theme continues with a review by Townsend and colleagues (2007) 
on complicated skin and skin structure infections (cSSSIs) and complicated intra-
abdominal infections (cIAIs) with a focus on tigecycline. These are the two most 
prominent sites for bacterial infections often after surgical procedures; many of 
which are caused by antibiotic resistant strains. Effective management of cSSSIs or 
cIAIs require timely instigation of appropriate antimicrobital therapy while in some 
select cases surgical intervention may also be required. Tigecycline is related to the 
tetracycline antibiotic class and is the ﬁ  rst of a new class of antimicrobials termed 
glycylcyclines. The authors give a clear and detailed description of how tigecycline 
overcomes the resistance mechanisms developed by several types of bacteria to 
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tetracyclines that most frequently involves protection of 
the ribosome and/or efﬂ  ux pumps. The microbiological, 
pharmacokinetics and pharmacodynamics of tigecycline 
are detailed in the review together with clinical efﬁ  cacy and 
safety issues. The authors conclude tigecycline to be a new 
effective treatment option for both cSSSIs and cIAIs with 
favourable in vitro activity against a wide variety of aerobic 
Gram-positive, Gram-negative and anaerobic organisms. The 
available clinical trials suggest similar efﬁ  cacy by tigecycline 
to comparator treatments for a variety of cSSSIs and cIAIs. 
The main adverse effect appears to be nausea and vomiting 
in some patients.
The arthritic diseases are prevalent and distressing 
conditions that are associated with signiﬁ  cant morbidity 
typiﬁ  ed by reductions in functional capacity and quality 
of life with attendant substantial healthcare expenditure. 
Development of speciﬁ  cally targeted biologic agents in 
recent years has greatly enhanced the therapeutic options 
for the treatment of the arthritic diseases rheumatoid 
arthritis, psoriatic arthritis, and ankylosing spondylitis 
(AS). AS is a inﬂ  ammatory joint disorder affecting the 
axial skeleton, peripheral large joints, some areas of 
tendon and ligaments attachment to bone and extra-
articular sites such as the anterior uvea. Current treatment 
approaches to AS are reviewed in the current issue by 
Walter Maksymowych (2007). These include the use of 
non-steroidal anti-inﬂ  ammatory agents and the anti-TNFα 
class of drugs. TNF is an attractive biologic target as it has 
been implicated as a major pro-inﬂ  ammatory player in a 
wide range of chronic inﬂ  ammatory conditions including 
AS. Three TNF antagonists are currently available 
inﬂ  iximab, a chimeric anti-TNF mAb, adalimumab, a 
fully human anti-TNF mAb and etanercept, a recombinant 
soluble p75 TNF-receptor-Fc fusion protein. These have 
been assessed in clinical trials in AS patients and it appears 
that all three available anti-TNFα agents appear to have 
similar efﬁ  cacy in improving the articular manifestations 
of AS with positive clinical responses being observed 
in 60% of patients. However, the author points out that 
several issues are outstanding including whether anti-
TNF therapies are disease modifying in that they prevent 
structural damage progression together with the issue of 
the efﬁ  cacy or otherwise of methotrexate therapy for AS 
in combination with anti-TNFα therapies.
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